Trial Profile
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; BI 1206 (Primary) ; BI 1206 (Primary) ; Rituximab
- Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors BioInvent International
- 20 Apr 2024 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 09 Feb 2024 According to a BioInvent International media release, company announced clinical supply agreement with AstraZeneca to support this study.Under the terms of the supply agreement, AstraZeneca will provide Calquenc for use in combination with BI-1206 and rituximab. This trial will be expanded to include the triplet arm.
- 09 Feb 2024 Drug Calquence (acalabrutinib) has been added to study protocol for the treatment of patients with follicular lymphoma who have progressed or are refractory to rituximab, according to a BioInvent International media release.